Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 60, Issue 21, Pages 9053-9066Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.7b01395
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81603000, 21602227, 21778059, U1502223]
- Science and Technology Program of Yunnan Province [2017FB135]
Ask authors/readers for more resources
Previously, vibsanin B (ViB) was found to preferentially target HSP90 beta compared to HSP90 alpha. In this study, multiple experiments, including pull-down assays of biotin-ViB with recombinant HSP90 beta-NTD, MD, CTD, and full-length HSP90 beta, molecular docking of ViB and its derivatives to the HSP90 CTD, and a inhibition assay of interaction of the HSP90 beta CTD with GST-tagged cyclophilin 40 (Cyp40) by ViB derivatives, suggest that ViB can directly bind to the HSP90 C-terminus. On the basis of the docking predictions and primary structure-activity relationships (SARs), a series of ViB analogues devised with focus on the C18 position, along with compounds derivatized at the C4, C7, and C8 positions, were designed and chemically synthesized. Compound 12f (IC50 = 1.12 mu M against SK-BR-3) exhibits great potency with drug-like properties. Overall, our findings demonstrate that compounds with the vibsanin B scaffold are a new class of HSP90 C-terminal inhibitors with considerable potential as anticancer agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available